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Summary
Acute myeloid leukaemia (AML) is the commonest indica-
tion for allogeneic stem cell transplantation (allo-SCT)
worldwide. The accumulated experience of allografting in
AML over the last four decades has provided critical insights
into both the contribution of the conditioning regimen and
the graft-versus-leukaemia effect to the curative potential of
the most common form of immunotherapy utilised in stan-
dard clinical practice. Coupled with advances in donor avail-
ability and transplant technologies, this has resulted in allo-
SCT becoming an important treatment modality for the
majority of adults with high-risk AML. At the same time,
advances in genomic classification, coupled with progress in
the accurate quantification of measurable residual disease,
have increased the precision with which allo-mandatory
patients can be identified, whilst simultaneously permitting
accurate identification of those patients who can be spared
the toxicity of an allograft. Despite this progress, disease
recurrence still remains a major cause of transplant failure
and AML has served as a paradigm for the development of
strategies to reduce the risk of relapse – notably the novel
concept of post-transplant maintenance, utilising pharmaco-
logical or cellular therapies.
Keywords: acute myeloid leukaemia, allogeneic stem cell trans-
plantation, graft-versus-host disease, graft-versus-leukaemia.
The number of adults allografted for acute myeloid leukae-
mia (AML) has risen sharply in the last decade (Passweg
et al., 2019) – a reflection of both the limitations of current
intensive chemotherapy (IC) regimens and also advances in
transplant technology which have increased donor availability
and reduced transplant toxicity. As a consequence, allogeneic
stem cell transplantation (allo-SCT) now plays a central role
in the management of adults with AML in first complete
remission (CR1). A number of factors have hitherto limited
the optimal deployment of allo-SCT in adults with AML.
Firstly, identification of CR1 patients whose outcome will be
poor if treated with IC alone who may consequently benefit
from an allograft’s augmented anti-leukaemic activity has
been imprecise. In recent years, the cytogenetic and molecu-
lar risk stratification of AML (Dohner et al., 2017), coupled
with early assessments of measurable residual disease (MRD)
(Schuurhuis et al., 2018), has substantially improved our
ability to identify allo-mandatory patients. Secondly, the
advent of novel stem cell sources for patients lacking a
matched sibling or unrelated adult donor, notably cord
blood and haploidentical donors, means that almost all eligi-
ble patients now have a potential donor. Thirdly, the demon-
stration that reduced intensity conditioning (RIC) regimens
ameliorate transplant toxicity, has dramatically increased the
number of transplant-eligible patients. As a result, allo-SCT
can now be delivered with acceptable toxicity in many fit
adults ≤75 years (Ringden et al., 2019). Nevertheless, despite
these advances, allo-SCT still fails to deliver long-term sur-
vival in a substantial proportion of patients. Although trans-
plant toxicity has fallen significantly in recent decades
(Gooley et al., 2010), the risk of disease recurrence has
remained stubbornly high and novel strategies with the
potential to reduce relapse risk are urgently required.
Allo-SCT in AML: a historical perspective
The first allogeneic transplant was performed for acute leu-
kaemia in 1957 (Thomas et al., 1957). Outcomes improved
steadily thereafter, consequent upon advances in supportive
care, graft-versus-host disease (GVHD) prophylaxis, and cru-
cially, HLA (human leucocyte antigen) typing (Thomas et al.,
1975). Landmark randomised trials in the 1990s demon-
strated that the intensity of the conditioning regimen was a
critical determinant of relapse risk in the setting of a
myeloablative conditioning regimen (MAC) (Clift et al.,
1990, 1991). In addition to the important role of the
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conditioning regimen in disease control, the contemporane-
ous observation of an inverse correlation between relapse risk
and the presence of GVHD identified the importance of the
graft-versus-leukaemia (GVL) effect in the delivery of a dur-
able anti-tumour effect (Weiden et al., 1979). Subsequent
studies have demonstrated the rapid emergence of a
potenta and highly manipulable, GVL effect within the first
three weeks post-transplant in patients allografted for AML
(Bacigalupo et al., 2000; Craddock et al., 2010).
The initial demonstration that allo-SCT improved out-
come in adults with AML in CR1 came from studies using a
‘donor versus no donor’ methodology, which demonstrated
showing improved disease-free survival and overall survival
in patients with intermediate or adverse risk cytogenetics
who had an available matched sibling donor (Cornelissen
et al., 2007; Koreth et al., 2009). Critically, this survival
advantage was only observed in patients under the age of 40
because of the toxicity of MAC regimens in older patients. In
contrast, for patients with good risk cytogenetics and a low
predicted risk of relapse when treated with chemotherapy
alone, studies failed to demonstrate improved overall survival
after allo-SCT, since any reduction in relapse risk is offset by
non-relapse mortality (NRM) (Schlenk et al., 2008). The
recent Recognition of the potency of the GVL effect led to
the subsequent development of RIC regimens, which in the
last 20 years have transformed transplant practice, permitting
delivery of a potentially curative GVL effect in large numbers
of older patients with AML, previously deemed too old for a
transplant (Giralt et al., 1997; Slavin et al., 1998).
Mechanisms and optimisation of a GVL effect
It is now well-established that the donor immune system can
mediate a powerful GVL effect in many haematological
malignancies. A general consensus has been that this is medi-
ated primarily through an alloreactive T cell response,
although there is increasing evidence that other mechanisms
are also in operation. In order to assess potential mecha-
nisms of GVL it is instructive to reflect on recent under-
standing of how AML can evade the immune system at the
time of initial disease presentation (Fig 1A). The innate and
adaptive arms of the immune response are both important
in tumour-specific responses – a striking observation is that
NK cell dysfunction is present in almost all patients at diag-
nosis (Fauriat et al., 2007). A range of mechanisms are
observed, including down-regulation of activatory receptors
on NK cells, reduction of NK ligands on the tumour and
decreased production of the potent NK-stimulatory cytokine
IL-15, secondary to acquisition of the FLT3 mutation
(Mathew et al., 2018). The observation that leukemic stem
cell populations often lack expression of NKG2D ligands,
and are thus able to evade NK surveillance, represents one
potential mechanism for tumour progression (Paczulla et al.,
2019). Conversely, less is known regarding the importance of
adaptive T cell immune responses during AML development,
although high-level expression of inhibitory checkpoint pro-
teins and increased proportions of T-regulatory cells are
observed at diagnosis (Williams et al., 2019).
Graft-versus-leukaemia may potentially be mediated by
both tumour-specific and allo-reactive recognition (Fig 1B).
The infusion of innate cells within the donor graft may be
capable of mediating an immediate tumour-specific response
and a recent analysis demonstrated relapse rates of 43% or
5% respectively for AML patients who received a donor stem
cell infusion with an NK cell count that was either below or
above the median cohort value (Maggs et al., 2017). This
NK-associated protection was most strongly correlated with
the infusion of DNAM + cytotoxic subsets. The potential
importance of NK-mediated GVL is further shown through
the correlation between a reduced rate of relapse, and both
post-transplant NK reconstitution within bone marrow as
well as the use of a donor with an ‘activatory’ KIR B geno-
type (Cooley et al., 2009). The contribution of an adaptive
immune responses against tumour-specific targets is less
clear, and although T cell recognition of proteins such as
WT1 or PRAME can develop, these are typically of low fre-
quency. Interestingly, the recent identification of high affinity
antibody responses against an AML-associated protein after
SCT indicates a potential hitherto neglected importance for
humoural immunity during GVL (van Balen et al., 2018).
Notwithstanding potential tumour-specific immune
responses, alloreactive recognition is clearly critical for dis-
ease control. NK cells which have a KIR-ligand mismatch
can mediate strong alloreactive responses, and epidemiologi-
cal and laboratory studies have demonstrated the importance
of this mechanism (Ruggeri et al., 2002). Indeed, myeloid
cells are uniquely sensitive to the activity of alloreactive NK
recognition and this may underlie some of the unique epi-
demiological features of GVL responses in AML patients.
Nonetheless, alloreactive CD4+ and CD8+ T cell recognition
of recipient minor histocompatibility antigens is thought to
be the primary effector mechanism of GVL. This response
may also manifest as GVHD but the tissue-specificity of allo-
recognition, as well as subtle differences in the intensity and
breadth of the T cell response, are thought to be important
in determining clinical outcome (van Bergen et al., 2017).
Further insights into the GVL response are now starting
to emerge through detailed studies of the mechanisms by
which AML can relapse after transplant (Fig 1C). Impor-
tantly, these are largely determined by the acquisition of
immune evasion by the tumour and again highlight the cen-
trality of the GVL response in tumour control. Mechanisms
include deletion of HLA class I genes, and downregulation of
NK cell targets, together with increased expression of inhibi-
tory checkpoint ligands and downregulation of HLA class II
expression (Vago et al., 2009; Christopher et al., 2018; Jan
et al., 2019; Toffalori et al., 2019). This latter point is of par-
ticular interest, giving emerging interest in the potential
importance of CD4+ tumour-specific responses in a wide
range of malignant disorders.
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These observations should now be translated into clinical
strategies to prevent and treat relapse relapse. Novel potential
approaches could include infusion of increased numbers of
NK cells at the time of stem cell donation and optimisation
of tumour and allo-specific responses through appropriate
donor selection, vaccination or immune modulation. Chi-
merism status will be a critical determinant of immune
recognition and low levels of donor T cell engraftment are
associated with increased disease relapse in some, but not all,
studies (Wong et al., 2017). Donor lymphocyte infu-
sion (DLI) is ineffective in overt morphological relapse
where antigen-specific cell therapy, including chimeric anti-
gen receptor T (CAR-T) cells, recognising AML-associated
proteins show preliminary promise. Checkpoint blockade has
modest efficacy in this setting and carries a risk of graft-ver-
sus-host disease (GVHD) (Davids et al., 2016; Daver et al.,
2018).
Stem cell source and alternative donors
More than 30 million adults are now registered as potential
volunteer donors on a range of national registries across the
world, substantially increasing transplant options for patients
lacking a matched sibling donor (MSD). Coupled with
increased availability of good quality cryopreserved umbili-
cal cord blood units and evidence that transplantation of
haploidentical stem cells can now be achieved with accept-
able toxicity, allo-SCT can now be contemplated in almost
all eligible patients. Unrelated adult donors and recipients
are routinely typed by high resolution typing at HLA loci A,
B, C, DRB1 and DQB1. Broadly equivalent clinical outcomes
are observed in patients with AML transplanted, using a
well-matched (8/8 or 10/10) unrelated volunteer donor
(VUD), compared to those achieved with an MSD (Yakoub-
Agha et al., 2006; Gupta et al., 2010; Schlenk et al., 2010) In
contrast, the use of a VUD donor with a one-antigen mis-
match is consistently associated with decreased overall sur-
vival, consequent upon an increased NRM and higher rates
of acute and chronic GVHD (Verneris et al., 2015; Ayuk
et al., 2018). Progressive levels of HLA mismatch further
reduce overall survival and are not routinely recommended
(Kollman et al., 2016; Ayuk et al., 2018), but may be modu-
lated in the future by improvements in GVHD prophylaxis,
such as the use of post-transplant cyclophosphamide as a
novel GVHD prophylaxis regimen (Battipaglia et al., 2019).
The other major determinant of outcome after unrelated
donor transplantation is donor age, with one study reporting
a decrease in patient survival of 5% for every 10-year incre-
ment in donor age (Kollman et al., 2016). As a consequence,
clinicians are increasingly called on to decide whether to pro-
ceed with an older sibling donor in patients with AML, for
whom a young well-matched volunteer donor has also been
identified. Current data are contradictory and although a
CIBMTR study has favoured the use of an MSD (Alousi
et al., 2013), a recent EBMT (European group for Blood and
Marrow Transplantation) study in patients allografted for
myelodysplasia showed a superior outcome using younger
unrelated donors (Ayuk et al., 2013). An emerging factor
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Fig 1. Representation of mechanisms determining immune recognition of acute myeloid leukaemia tumour cells by NK and T cells (A) at the
time of disease presentation, (B) during a graft-versus-leukaemia response and (C) at the time of disease relapse after transplant.
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complicating the choice of an older MSD is the possible
influence of the presence of clonal haematopoiesis of indeter-
minate potential (CHIP) on transplant outcome. Interest-
ingly, a large recent retrospective analysis observed that the
presence of CHIP did not adversely impact survival and
intriguingly was associated with a higher risk of chronic
GVHD and lower risk of relapse (Frick et al., 2019). Prospec-
tive studies on the impact of the presence of CHIP on both
transplant outcome and donor safety are now a priority.
The likelihood of identifying a suitably matched unrelated
donor has risen to over 75% in Caucasian patients within
the last decade (Gragert et al., 2014), but remains unaccept-
ably low in some ethnic groups. The recent demonstration of
encouraging transplant outcomes using single or double
umbilical cord blood (UCB) units, matched at 4/6 or
more HLA loci, is a major advance for patients lacking a
suitably matched unrelated donor. Although associated with
a modest increase in NRM, long-term survival rates in
patients transplanted using cord units of at least a 4/6 match
with a high total nucleated cell dose are now comparable to
those achieved using an MSD or well-matched VUD in
patients with AML transplanted using either a MAC or RIC
conditioning regimen (Laughlin et al., 2001; Eapen et al.,
2010; Brunstein et al., 2011). This reflects a steady reduction
in the TRM (transplant-related mortality) of cord blood
transplants, but is also a possible reduction in relapse risk,
particularly in patients with detectable MRD at the time of
transplant (Milano et al., 2016; Shouval et al., 2019). Impor-
tantly, the toxicity of cord blood transplantation continues
to fall, because of the meticulous selection of appropriately
matched cord blood units with a high nucleated cell dose,
the omission of ATG in GVHD prophylaxis, prompt treat-
ment of the engraftment syndrome, and the use of letermovir
to reduce the risk of CMV reactivation (Barker et al., 2017).
As such, a cord blood transplant, using appropriately selected
cord blood units, may possibly in future become the pre-
ferred donor source, even in patients with an available MSD,
for selected patients with high-risk AML.
More recently, it has been demonstrated that use of a
HLA-haploidentical family member can be associated with a
modest NRM and acceptable risk of severe GVHD, if either
post-transplant ATG or cyclophosphamide is used as GVHD
prophylaxis (Luznik et al., 2008; Lee et al., 2009). A number
of retrospective registry studies show encouraging outcomes
after haploidentical transplantation, using post-transplant
cyclophosphamide as GVHD prophylaxis, in adult AML.
However, in the absence of prospective trials, the potential
selection bias inevitable in registry analyses does not make it
possible to confidently state whether a haploidentical donor
should be preferred to a 9/10 or 10/10 unrelated adult donor
(Piemontese et al., 2017). Two large recent EBMT studies
have demonstrated continued incremental improvements in
the outcome of patients with high-risk AML transplanted
using cord blood or haploidentical grafts, consistent with the
possibility that selected patients with high-risk AML may
benefit from an alternative stem cell donor (Ruggeri et al.,
2015; Versluis et al., 2017). The results from multi-centre
phase III randomised controlled trials of RIC SCT, which
compare UCB or haploidentical donors (such as BMT CTN
1101; ClinicalTrials.gov Identifier: NCT01597778), are there-
fore awaited with interest, although it is noteworthy that
transplant technologies have evolved during this period,
which will make interpretation of such studies challenging.
Towards a personalised conditioning regimen
for allogeneic transplantation in AML
Conditioning regimens aim to deliver durable stem cell
engraftment and maximal anti-leukaemic activity, with mini-
mal attendant toxicity. They are increasingly personalised to
reflect patient- and donor-specific characteristics. The ambi-
tion of achieving leukaemia-free survival without the burden
of significant GVHD is reflected in the increasingly adopted
endpoint of ‘GVHD relapse-free survival’ (GRFS) (Holtan
et al., 2015). The comparative assessment of conditioning
regimens, so essential to optimising transplant outcome, is
complicated by the impact of patient and donor-specific fac-
tors on both transplant toxicity and relapse risk. Specifically
the risk of disease recurrence is determined by both tumour
biology and pre-transplant remission status, whilst transplant
toxicity is determined by patient age, co-morbidity and
donor characteristics.
Until recently, conditioning regimens uniformly utilised
myeloablative chemo-radiotherapy, which imposes an absolute
requirement for infusion of donor stem cells in order to avoid
irreversible cytopenia. The development of reduced intensity
regimens, which result in variable degrees of cytopenia, and by
definition utilise ≤8 Gy TBI or ≤8 mg/kg busulfan (Bacigalupo
et al., 2000), have dramatically increased the upper age limit
for allo-SCT and are now the commonest form of condition-
ing regimen deployed in adult AML allografts. Non-myeloab-
lative (NMA) regimens typically utilising fludarabine in
combination with 2 Gy, do not require stem cell support, but
are of limited utility in adult AML. The interpretation of
recent randomised trials aimed at addressing the important
question of whether a MAC or RIC regimen should be pre-
ferred in adults allografted for AML in CR1, have been com-
plicated by striking regimen-specific differences in toxicity and
relapse associated with distinct MAC and RIC regimens (Scott
et al., 2017; Fasslrinner et al., 2018). Future trials aimed at
determining the optimal conditioning regimen in AML must
therefore compare specific regimens and also incorporate both
molecularly-based disease risk as well as pre-transplant embed-
ded MRD assessment, which are such important determinants
of relapse risk post-transplant.
What is the optimal MAC regimen in adult AML?
The MAC regimens most commonly used in AML have been
combinations of cyclophosphamide (Cy) with either total
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body irradiation (TBI)- Cy/TBI- or busulfan (Bu)- Bu/Cy.
Both regimens are still widely used in fit patients with high-
risk disease, transplanted using an MSD or VUD. The major-
ity of studies comparing Cy/TBI with a Bu/Cy regimen (utilis-
ing oral Bu) have demonstrated broadly equivalent outcomes
(Socie et al., 2001; Nagler et al., 2013). However, the advent
of intravenous preparations of Bu associated with more pre-
dictable pharmacokinetics and an improved toxicity profile
has reduced the toxicity of the Bu/Cy regimen; a prospective
cohort study from the CIBMTR also demonstrated superiority
of the iv-Bu/Cy regimen, particularly for patients in CR1 (Bre-
deson et al., 2013). More recently, a large randomised trial
compared the novel FluBu4 (128 mg/kg four days of IV
busulfan) regimen with iv-Bu/Cy for patients with AML in
CR1. Whilst outcomes were similar between the groups, the
FluBu4 regimen resulted in a significant reduction in NRM.
As a consequence, Flu/iv-BU is now an increasinly
utilised MAC regimen in fit adults with AML in CR (Giralt,
2015), although irradiation-based regimens still have an
important role in the small number of patients presenting
with either CNS involvement or an extramedullary sarcoma.
What is the optimal RIC regimen in adult AML?
The optimal RIC regimen in older adults with AML has not
been established. It is clear that Flu-based regimens, typically
formulated as Flu/Bu2 (64 mg/kg, two days of IV busulfan)
(Slavin et al., 1998), Flu/melphalan (140 mg/m2) (Giralt et al.,
1997) or Flu/Cy (1 g/m2 9 2) (Davies et al., 2018), differ in
terms of both anti-tumour activity and toxicity. There are
regrettably very few randomised trials of RIC regimens in
AML, but it is of interest that a randomised comparison
between the widely-used Flu/Bu2 regimen and the Seattle Flu/
2 Gy TBI NMA regimen demonstrated equivalent overall sur-
vival, but an increased NRM and reduced relapse rate with
the Flu/Bu2 regimen compared with the NMA regimen,
underlining the importance of comparing specific reduced-
intensity regimens in the future (Blaise et al., 2013).
Should a RIC regimen be preferred in all adults
allografted for AML in CR1?
One of the most important, but still unresolved, questions in
AML is whether RIC regimens should replace MAC regimens
for all patients or remain restricted to an older age group, or
those with significant co-morbidities. Previous registry stud-
ies have demonstrated broadly equivalent outcomes in
patients with AML, transplanted using an MAC or RIC regi-
men, noting that the lower NRM of a RIC regimen is offset
by an increased risk of disease relapse. These retrospective
studies have been difficult to apply to routine clinical prac-
tice because of the selection bias inherent within registry-
based studies and the heterogeneity of the MAC and RIC
regimens included in these comparisons (Martino et al.,
2006; Martino et al., 2013). Paradoxically, given the
importance of the question, recruitment to practice-inform-
ing prospective randomised trials comparing outcomes
between MAC and RIC regimens has been challenging, but
three have been reported in patients with AML or MDS
(Bornhauser et al., 2012; Kroger et al., 2017; Scott et al.,
2017; Fasslrinner et al., 2018). Two studies observed equiva-
lent outcomes in patients transplanted using a busulfan-
based MAC or RIC regimen, but both studies recruited
slowly and were consequently under-powered (Kroger et al.,
2017; Fasslrinner et al., 2018). In contrast, a US BMT Clini-
cal Trials Network study observed improved disease-free sur-
vival in patients transplanted using a MAC regimen,
although survival outcomes were equivalent (Scott et al.,
2017). Interpretation of this trial is, however, complicated by
both an unexpectedly high relapse risk in patients allocated
to receive an RIC regimen and very low relapse rate in the
MAC arm. Critically, none of the randomised trials reported
to date have incorporated pre-transplant MRD evaluation
which, coupled with disease biology, is now recognised as the
most important predictor of relapse. On the basis of available
data it is therefore not possible to support, with confidence,
the conclusion that RIC regimens are superior to MAC regi-
mens in adults with AML in CR1. Pragmatically, since the
myeloablative Flu/Bu4 regimen can be delivered with accept-
able rates of toxicity to most fit patients up to the age of
55 years, this should probably serve as the default regimen in
AML CR1 patients, with an RIC regimen being preferred in
older patients or those with significant co-morbidities (Blaise
et al., 2013; Malard et al., 2017).
Which patients with AML in CR1 should
proceed to transplant?
In order to optimise transplant outcome, it is vital that
patients who are deemed likely to benefit from an allograft
in CR1 should proceed to transplant as swiftly as possible.
An important factor influencing the decision to allograft in
CR1 concerns the wisdom of reserving transplants for
patients who relapse and achieve a second CR with salvage
chemotherapy. The outcome of relapsed AML remains poor,
reflecting both the small chance of achieving a second CR
after salvage chemotherapy in patients with an intermediate
or adverse risk karyotype, and inferior transplant outcomes
in patients allografted in second CR (Breems et al., 2005;
Ganzel et al., 2018). Consequently, once it has been decided
that a patient is likely to derive a significant survival benefit
from allo-SCT, it is unwise to postpone transplantation
unless it is deemed that the patient has a high chance of
achieving a second CR with salvage chemotherapy, or for
reasons of personal considerations.
The decision-making process in CR1 patients
The pivotal question in deciding whether or not to recom-
mend an allograft in CR1 is whether the reduction in relapse
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risk delivered by a transplant outweighs the attendant NRM.
Studies show that, as a broad estimate, allo-SCT halves the
relapse risk for CR1 patients in comparison with chemother-
apy, a finding evident in all cytogenetic risk groups (Cor-
nelissen et al., 2012a,b). As has been so insightfully
articulated by Cornelissen et al., transplant decisions should
therefore be made on the basis of an individualised assess-
ment of both the predicted risk of disease relapse, if patients
are treated with chemotherapy alone, and the NRM, calcu-
lated on the basis of patient age, fitness and donor source.
Since the NRM of fit adults transplanted using a matched
sibling or unrelated donor can be reliably predicted to be in
the region of 15%, patients with a relapse risk >50% are
likely to benefit from the attendant halving of relapse risk
delivered by an allograft, using a well-matched donor. Fur-
thermore, patients with a higher risk of disease relapse can
be reasonably considered as transplant candidates, even when
the predicted NRM is higher on account of patient co-mor-
bidities or increased patient:donor HLA disparity. By similar
reasoning, patients with a relapse risk ≤40% after chemother-
apy are very unlikely to derive any survival advantage from
an allograft, given the small but finite risk of transplantation,
even in the most favourable of circumstances (Table I).
Risk stratification in patients treated with IC alone
The last decade has seen major progress in predicting the risk
of disease relapse in adults with AML treated with IC. Fac-
tors associated with a higher risk of disease relapse include
increased patient age, a high white blood cell count at pre-
sentation, a diagnosis of secondary AML, the presentation
karyotype, and the delayed acquisition of morphological
remission (Dohner et al., 2017). More recently, the develop-
ment of a genomic classification of AML, based on the iden-
tification of mutations in transcription factors, epigenetic
modifiers, spliceosome, cohesin complex, and signaling path-
ways (Papaemmanuil et al., 2016) have underpinned the
development of more accurate risk stratification models.
These have been encapsulated in the 2017 ELN classification,
which now includes presentation karyotype and mutations in
NPM1, FLT3 and CEBPA, RUNX1, ASXL1 and TP53 genes
to provide a genetic risk stratification of AML (Dohner et al.,
2017). In the future, we can anticipate the greater precision
in outcome prediction provided by prospective evaluation of
large genomically characterised cohorts treated with IC alone,
as well as hopefully with allo-SCT, to result in further refine-
ment of such models (Gerstung et al., 2017).
Immunophenotypic or molecular quantification of MRD
after induction or consolidation therapy also provides an
important independent predictor of relapse risk in AML and
can be used to refine conventional morphological assessment
of response (Terwijn et al., 2013; Ivey et al., 2016; Freeman
et al., 2018) (Fig 2). More recently, next generation sequenc-
ing technologies have been shown to improve risk stratifica-
tion in combination with conventional MRD methodologies,
incorporating strategies to exclude mutations in genes associ-
ated with age-related clonal hematopoiesis (Jongen-Lavrencic
et al., 2018). When used for risk stratification, it is important
to note that the specific impact of MRD status on relapse
risk is critically dependent on patient age, cytogenetic and
molecular subgroup, and time of assessment.
Predicting transplant outcome – the role of donor source
and patient co-morbidities
The critical determinants of transplant-related death after
allo-SCT for AML are patient age and fitness, the degree of
HLA disparity and conditioning regimen intensity. Two scor-
ing systems have been shown to predict transplant outcome,
specifically NRM, in the setting of allo-SCT for AML. The
EBMT score was the first to demonstrate that a scoring sys-
tem which captured age, donor:HLA disparity and disease
status was able to identify patient populations whose NRM
ranged from 15% – 45% (Gratwohl et al., 2009). The HCT-
CI, derived using a weighted assessment of 17 co-morbidities,
has also been shown to predict NRM and outcome after allo-
SCT and has been validated in AML (Sorror et al., 2007).
Predicting the impact of patient fitness on transplant out-
come is however still imprecise, particularly in older patients,
and the ability of a machine-based learning model to increase
Table I. Selection of patients with acute myeloid leukaemia in first complete remission for allogeneic stem cell transplantation (allo-SCT), based
on relapse risk (D€ohner et al., 2017; Schuurhuis et al., 2018) and estimate of non-relapse mortality (NRM) (Sorror et al., 2014), adapted from
Cornelissen and Blaise (2016).
2017 ELN Risk
stratifications by genetics
MRD after cycle 2
chemotherapy
Estimated risk of relapse, based on
consolidation with:
Maximal tolerated NRM
prognostic scores for allo-SCT
to be beneficial
Chemotherapy alone (%) Allo-SCT (%) HCT-CI score NRM risk (%)
Favourable Negative 25–35 15–20 N/A (<1) 5
Positive 70–80 30–40 ≤3–4 <30
Intermediate Negative 50–60 25–30 ≤2 <20
Positive 70–80 30–40 ≤3–4 <30
Adverse N/A >90 45–55 <5 <35
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the accuracy of prediction therefore represents a potentially
important advance (Shouval et al., 2015). In the meantime, it
remains a fact that one of the most challenging aspects of
daily transplant practice is the accurate identification of older
patients with marginal co-morbidities, for whom the varied
toxicities of transplant represent an acceptable risk – to both
patient and physician.
The role of allo-SCT in the management of AML beyond
CR1
Whilst a small proportion of patients with AML in second
CR achieve long-term survival if treated with salvage
chemotherapy alone, compelling data identify allogeneic
transplantation as the preferred curative option (Gale et al.,
1996). Long-term survival rates in the region of 30–50% have
been reported after transplantation from either a matched
sibling or unrelated adult donor (Tauro et al., 2005; Gilleece
et al., 2019). Encouraging results are also reported in patients
transplanted with alternative donors. In patients who have
achieved a morphological second CR, it is wise to proceed
immediately to transplant, providing the patient is fit, a
donor has been identified, and there is no evidence support-
ing further courses of chemotherapy prior to transplantation.
Whilst a rigorous comparison of MAC and RIC regimens
has not been performed in fit patients <50 years, a MAC reg-
imen should probably be preferred.
Ten to 40 per cent of adults with newly diagnosed AML
fail to achieve a morphological complete remission (CR)
after two courses of induction chemotherapy (Ferguson
et al., 2016) and are therefore defined as primary refractory
AML (PREF AML; Dohner et al., 2017). Evidence that allo-
SCT can deliver long-term survival in a significant propor-
tion of patients with PREF AML has been accumulating over
the last decade and represents an important advance for this
sizeable patient population for whom no other effective ther-
apy exists (Duval et al., 2010; Ferguson et al., 2016). The
optimal conditioning regimen in patients with PREF AML
remains a matter of conjecture. Whilst MAC regimens
should probably be preferred in fit patients <50 years,
encouraging results have also been reported using the
sequential FLAMSA regimen which incorporates additional
tumour debulking with cytosine arabinoside and amsacrine,
prior to a Flu-based RIC regimen (Schmid et al., 2006).
Considerations for elderly patients with AML
The incidence of AML rises sharply with age. Particular chal-
lenges associated with the management of older patients with
AML include the increased proportion of patients with
adverse cytogenetic or molecular characteristics, as well as
challenges in assessment of co-morbidities and fitness for
intensive therapies (Schiffer et al., 1989). Furthermore, clini-
cians have traditionally been more reticent to refer elderly
patients for allo-SCT (Estey et al., 2007), despite emerging
evidence that for a proportion, at least, of older patients,
allografting represents an important potentially curative
treatment modality. RIC conditioning regimens have resulted
in an increase in the proportion of allo-SCT patients >70
years who are transplanted (Muffly et al., 2017) with accept-
able two-year overall survival rates in a large EBMT registry
cohort (Ringden et al., 2019). A prospective phase II trial
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Fig 2. Measurable residual disease measurement methods in acute myeloid leukaemia.
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demonstrated particularly encouraging results, confirming
that an RIC regimen can safely be delivered to patients aged
60–74 years old with AML in CR1 (Devine et al., 2015).
There is some debate as to how much age contributes to
transplant risk, with some suggestion that it is limited in iso-
lation (McClune et al., 2010; Sorror et al., 2011; Chevallier
et al., 2012).
A fundamental challenge in optimising transplant manage-
ment of older patients remains the identification of those
who can safely tolerate an allograft. At present, the selection
of patients is based on a co-morbidity scoring performed
prior to transplantation. The most commonly used co-mor-
bidity score, the HCT-CI (Sorror et al., 2005), was estab-
lished for patients with a median age of 44. A subsequent
update of this model to include older patients (Sorror et al.,
2014) has been shown to be of particular value in transplant
decision-making for patients >60 years, in whom the NRM
of patients with a HCT-CI of 0-1 is broadly similar to that
observed in younger patients, in contrast to the NRM of
60% observed in patients with a score of 2 or greater (Niko-
lousis et al., 2015). An additional comprehensive geriatric
assessment tool has been developed to take into account a
more sophisticated functional status of patients, prior to
transplantation (Muffly et al., 2013).
Reducing relapse risk
Disease relapse remains the major cause of treatment failure
in patients allografted for AML and ranges between 30% and
80% according to disease stage at transplant, presentation
karyotype, and the intensity of post-transplant immunosup-
pression (Bacigalupo et al., 1991; Tallman et al., 2007; Crad-
dock et al., 2010, 2011). Increased understanding of the
factors determining risk of relapse has permitted the develop-
ment of a range of pre-, peri- and post-transplant strategies
with the potential to reduce this problem (Fig 3). Broadly,
these include reducing the disease load as assessed by MRD
status prior to transplant, increasing conditioning regimen
intensity without incurring additional toxicity, and maximis-
ing a GVL-response post-transplant.
Reduction in pre-transplant MRD status as a strategy to
reduce the risk of relapse
A number of retrospective analyses have identified pre-trans-
plant MRD levels to be an important prognostic risk factor
of relapse, although it should be noted that prospective stud-
ies are lacking (Buckley et al., 2017). A very important ques-
tion is whether interventions aimed at reducing the pre-
transplant MRD burden can improve transplant outcome.
Retrospective registry studies have failed to demonstrate that
the number of cycles of IC delivered prior to either a MAC
or RIC transplant can impact on relapse risk, but impor-
tantly none of these studies included MRD assessment (Tall-
man et al., 2000; Warlick et al., 2014). Two recent
randomised trials examining the respective impact of
midostaurin or CPX-351, compared with DA induction
chemotherapy, in addition to demonstrating improved sur-
vival in the experimental arm, also showed improved trans-
plant outcome (Stone et al., 2017; Lancet et al., 2018).
Neither study included MRD quantification and the reason
for the improved outcome remains conjectural, but it is
tempting to speculate that augmented induction chemother-
apy was associated with a lower MRD load pre-transplant.
Consequently, there is an urgent need for prospective ran-
domised studies which examine the impact of pre-transplant
therapeutic intervention on both pre-transplant MRD status
and relapse risk post-allograft.
Optimising the conditioning regimen
Given the central importance of the conditioning regimen in
determining relapse risk, there remains an important require-
ment for randomised comparisons of both MAC and RIC
regimens, particularly in high-risk patients. Critical to the
interpretation of such studies is a recognition that the anti-
tumour properties of both regimens are also critically
impacted by GVHD prophylaxis strategy, including the
intensity of post-transplant immunosuppression and whether
or not T cell depletion is utilised (Pasquini et al., 2012).
Attempts to add sequential chemotherapy to RIC regimens,
such as the FLAMSA schedule, has been reported to reduce
disease relapse in high-risk AML in single arm studies, and
the results of a randomised comparison with the FB2 regi-
men performed by the UK NCRI AML Group is awaited
(Schmid et al., 2005; Malard et al., 2017).
Post-transplant strategies to reduce transplant risk
The hypothesis that pharmacological intervention in the early
post-transplant period can manipulate the kinetics of disease
relapse and may have the potential to improve transplant
outcome was first established in chronic myeloid leukaemia
using imatinib (Olavarria et al., 2007), and has been
extended to patients allografted for AML and MDS (Crad-
dock, 2013). Conceptually, there are a number of mecha-
nisms by which adjunctive post-transplant therapies might
reduce the risk of disease recurrence (Fig 4). Firstly, drugs
with inherent anti-leukemic activity may simply augment the
anti-tumour activity of the transplant. Secondly, the manipu-
lation of the kinetics of disease relapse may give the emerg-
ing allo-immune effect a competitive advantage, buying time
for the establishment of a clinically significant GVL effect,
prior to disease relapse. Thirdly, postponement of disease
relapse can in principle permit delaying the administration of
DLI until such time that the risk of severe GVHD is reduced.
Finally, post-transplant pharmacological therapies may
directly modify the allo-reactive response, potentially through
up-regulation of tumour antigens (Choi et al., 2010; Good-
year et al., 2012) or acceleration of T cell reconstitution
(Mathew et al., 2018).
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One of the most promising post-transplant maintenance
strategies currently under examination is the administration
of FLT3 inhibitors in patients allografted for FLT3 ITD+
AML. A number of retrospective studies have demonstrated
a reduced risk of disease relapse in those patients allo-
grafted for FLT3 ITD+ AML, who received post-transplant
sorafenib maintenance (Brunner et al., 2016), but do not
currently justify the routine administration of FLT3 inhibi-
tors in this patient group. The results of the US CTN1506
trial examining the impact of post-transplant gilteritinib
maintenance therapy in patients allografted for Flt3+
AML is therefore eagerly awaited (NCT02997202) (Levis
et al., 2019).
An alternative and promising approach is peri- or post-
transplant administration of the DNMT inhibitors AZA or
decitabine, which are also both well-tolerated in this clinical
setting (Cruijsen et al., 2016). Both agents have the capacity
to induce CD8+ T cell responses to candidate tumour anti-
gens, including MAGE antigens, which are not ordinarily
observed post-transplant, and prospective randomised trials
of the impact of such agents as post-transplant maintenance
are ongoing (Craddock et al., 2016a).
Management of relapsed AML post-transplant
The outcome for patients who relapse after allograft remains
very poor, with a two-year OS of 14–25%, although the
small number of patients who achieve a second CR after
salvage therapy can have a promising outcome after either a
second allograft or DLI (Schmid et al., 2012, Christopeit
et al., 2013) (Fig 5). Pivotal to the development of novel
treatment strategies is the development of a better under-
standing of the biology of disease relapse post-transplant.
It is increasingly recognised that clonal evolution is a fun-
damental mechanism underlying disease relapse post-trans-
plant (Quek et al., 2016; Jan et al., 2019). The observation
that potentially druggable mutations, such as FLT3 ITD, are
commonly lost at relapse may be interpreted as supporting
the exploration of maintenance strategies which utilise drug
or cellular therapies with broader anti-tumour specificity as
opposed to targeted therapies. There is also increased evi-
dence of acquired dysregulation between the donor immune
system and recipient haematopoiesis as an important mecha-
nism of disease relapse (Fig 1). Acquired uniparental isodis-
omy of the HLA genes on chromosome 6p, such that the
haplo-mismatched alleles are lost, is commonly observed in
patients who relapse after a haploidentical transplant(Vago
et al., 2009). A similar process, and direct HLA gene dele-
tion, can occasionally be seen after VUD SCT (Toffalori
et al., 2012; Hamdi et al., 2015; Jan et al., 2019) but appears
to be a rare event after MSD. The recent discovery of tran-
scriptional downregulation of HLA Class II expression in leu-
kaemia cells at relapse demonstrates another means by which
the GVL mechanism is circumvented (Toffalori et al., 2019).
A major challenge in the management of relapsed disease
is the tolerability of salvage therapies in post-transplant
patients. Azacitidine has recently been shown to be a well-
tolerated and active salvage agent in patients relapsing post-
allograft (Craddock et al., 2016b), and may also be combined
with DLI (Schroeder et al., 2015). A wave of novel agents
have also shown promise. A recent trial of lenalidomide and
azacitidine showed overall clinical responses of 47% in a
-
Fig 3. Strategies to reduce the risk of disease relapse in patients allografted for acute myeloid leukaemia.
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Fig 4. Post-transplant maintenance strategies to reduce relapse risk in patients allografted for acute myeloid leukaemia. (A) Pharmacological
acceleration of a graft-versus-leukaemia (GVL) effect; (B) pharmacological manipulation of the kinetics of disease relapse to ‘buy’ time for the
genesis of a GVL effect.
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Fig 5. Management of relapse postallogeneic stem cell transplantation in acute myeloid leukaemia, including immune modulation and
chemotherapy strategies.
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phase I clinical trial (Craddock et al., 2019). Quizartinib and
gilteritinib are active in patients with FLT3 ITD+ disease and
appear superior to high dose salvage chemotherapy (Perl
et al., 2017; Cortes et al., 2019). An important question in
coming years will be whether pre-emptive interventions for
MRD positive disease will be beneficial for patients. Novel
immunotherapeutic strategies will be important, but many
remain at either a pre-clinical or early phase trial setting.
The fundamental challenge is of identifying a target antigen
that is expressed specifically and highly on AML cells (Perna
et al., 2017). Bi-specific antibodies (BiTE) directed against
AML cells through either CD33 (Herrmann et al., 2018) or
CD123 (Al-Hussaini et al., 2016), can be brought into con-
tact, and activate T cells, through CD3. CAR-T have also
been explored. Targets include CD33, CD123 and NKG2DL
(Ritchie et al., 2013), and some early short-lived responses,
but results of further clinical trials are awaited.
Future challenges
The last decade has seen a remarkable increase in the number
of therapeutic opportunities with the potential to reduce the
risk of disease relapse in patients allografted for AML. A future
priority must be to effectively deliver randomised trials of
transplant regimens and post-transplant maintenance strate-
gies, incorporating both genomic and pre-transplant MRD
studies. This will require far-reaching improvements in our
capability to deliver practice-informing transplant trials. Much
can be learned from the remarkable success of the accelerated
trials network developed by the US BMT Clinical Trials Net-
work (Network, 2016). Attention must also be given to the
routine integration of genomics and biomarker discovery pro-
grammes as well as developing new models of partnership
between academia and the pharmaceutical sector. By accelerat-
ing the delivery of practice informing trials to regulatory stan-
dards, such innovative networks will drive effective
collaboration between the transplant community and the bio-
pharmaceutical sector, to the ultimate benefit of patients.
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